Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version
Changes to This Summary (01/29/2019)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about the results of a single-institution retrospective review that identified 14 patients with head and neck alveolar rhabdomyosarcoma who were treated with multiagent chemotherapy and radiation therapy to the primary site and clinically involved nodes (cited Ludmir et al. as reference 55 and level of evidence 3iiiDiii).
Added text about the results from a pooled analysis of North American and European cooperative groups of patients with paratesticular rhabdomyosarcoma, including prognostic features, survival outcomes, and treatment options (cited Walterhouse et al. as reference 108 and level of evidence 3iiA).
Added Fernandez-Pineda et al. and Jensen et al. as references 132 and 133, respectively.
Added text about the results of two Children's Oncology Group pilot trials in patients with high-risk rhabdomyosarcoma who were treated with intensive multiagent chemotherapy plus cixutumumab or temozolomide (cited Malempati et al. as reference 166 and level of evidence 3iiDi).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No comments:
Post a Comment